References
- Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal cytotoxic, or immune therapy: 133 randomised trials involving 31000 relapses and 24000 deaths among 75000 women. Lancet 1992; 339: 1–15; 71–85
- Fisher B., et al. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol 1990; 8: 1005–18
- Gelber R. D. Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival. Lancet 1996; 347: 1066–71
- Kang Y., Cortina R., Perry R. R. Role of c-myc in tamoxifen-induced apoptosis in estrogen-independent breast cancer cells. J Natl Cancer Inst 1996; 88: 279–84
- Pérez-López F. R. Effects of tamoxifen in women with fibrocystic disease of the breast. Recent Deuelopments in Gynecological Endocrinology, A. R. Genazzani, A. D. Genazzani, G. D'Ambrogio. Parthenon Publishing Group, Carnforth 1992; 1: 509–16
- Pérez-López F. R. Mammary and metabolic effects related with tamoxifen treatment in postmenopausal women. Proceedings of the 8th International Congress on the Menopause. Sydney 1996, in press